SCHEMBL6046771

SCHEMBL6046771

CCn1c(=O)c2c(C)[nH]nc2c2cc(-c3ccc(CN4CCc5ccccc5C4)s3)ccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 6/20 0.47
ABCC1 P33527 1/20 0.37
CD44 P16070 1/20 0.36
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
HSD17B10 Q99714 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
AURKA O14965 1/20 0.35
KDR P35968 1/20 0.35
AURKB Q96GD4 1/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
PARP1 P09874 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6046756 0.87 CHEK1 (0.44) CHEK1AURKAKDRAURKBPDE4A
SCHEMBL6046709 0.87 CHEK1 (0.44) CHEK1AURKAKDRAURKBPDE4A
SCHEMBL6046710 0.83 CHEK1 (0.42) CHEK1AURKAKDRAURKBPDE4A
SCHEMBL6046867 0.82 CHEK1 (0.43) CHEK1ALDH1A1KDM4EHSD17B10AURKA
SCHEMBL6046812 0.82 CHEK1 (0.43) CHEK1ALDH1A1KDM4EHSD17B10AURKA
SCHEMBL6046830 0.82 CHEK1 (0.42) CHEK1PARP1
SCHEMBL6046825 0.82 CHEK1 (0.40) CHEK1AURKAKDRAURKBPDE4A
SCHEMBL6046764 0.80 CHEK1 (0.53) CHEK1ALDH1A1KDM4EHSD17B10AURKA
SCHEMBL6046796 0.80 CHEK1 (0.45) CHEK1ALDH1A1KDM4EHSD17B10AURKA
SCHEMBL6046732 0.80 CHEK1 (0.47) CHEK1AURKAKDRAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060035920-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-02-16 US disclosed
WO-2005118583-A1 2, 5-DIHYDRO-PYRAZOLO`4, 3-C!QUINOLIN-4-ONES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035920-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 CHEK1 3/4885ABCC1 1064/4885CD44 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.